News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
FDA Delays Action on Johnson & Johnson (JOBS) Seizure Drug
August 24, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
AP — Johnson & Johnson has reported that federal health regulators have delayed a decision on its experimental seizure drug carisbamate.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Johnson & Johnson Family of Companies
MORE ON THIS TOPIC
Approvals
Regeneron racks up another first as FDA greenlights generalized myasthenia gravis RNA drug
November 19, 2026
·
3 min read
·
Heather McKenzie
Insights
The untapped potential of drug repurposing
November 19, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Approvals
GSK nabs FDA greenlight for second lung cancer asset from Nuvalent buy
November 18, 2026
·
2 min read
·
Tristan Manalac
Lung cancer
Summit’s rejection letter reveals FDA’s deeper concerns about trial design, safety
November 18, 2026
·
3 min read
·
Annalee Armstrong